Matt Hewitt
Stock Analyst at Craig-Hallum
(2.62)
# 2,066
Out of 5,148 analysts
43
Total ratings
54.05%
Success rate
2.63%
Average return
Main Sectors:
Stocks Rated by Matt Hewitt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLP Simulations Plus | Maintains: Buy | $45 → $36 | $12.13 | +196.78% | 8 | Jun 13, 2025 | |
| CSBR Champions Oncology | Maintains: Buy | $8 → $12 | $6.07 | +97.69% | 4 | Mar 12, 2025 | |
| CLOV Clover Health Investments | Initiates: Buy | $6 | $2.04 | +194.12% | 1 | Dec 17, 2024 | |
| BLFS BioLife Solutions | Maintains: Buy | $30 → $32 | $22.52 | +42.10% | 4 | Nov 13, 2024 | |
| OMCL Omnicell | Maintains: Buy | $45 → $64 | $41.25 | +55.15% | 6 | Oct 31, 2024 | |
| LGND Ligand Pharmaceuticals | Maintains: Buy | $135 → $140 | $202.55 | -30.88% | 3 | Jul 9, 2024 | |
| NOTV Inotiv | Maintains: Buy | $25 → $10 | $0.31 | +3,167.97% | 3 | May 16, 2024 | |
| SDGR Schrödinger | Maintains: Buy | $35 → $30 | $12.15 | +146.91% | 3 | May 2, 2024 | |
| MXCT MaxCyte | Initiates: Buy | $7 | $0.79 | +788.21% | 1 | Nov 29, 2023 | |
| RGEN Repligen | Maintains: Buy | $207 → $200 | $124.97 | +60.04% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $1.76 | +468.18% | 1 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $67 → $30 | $5.16 | +481.40% | 5 | Apr 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $400 | $0.26 | +153,687.01% | 1 | Jan 4, 2022 |
Simulations Plus
Jun 13, 2025
Maintains: Buy
Price Target: $45 → $36
Current: $12.13
Upside: +196.78%
Champions Oncology
Mar 12, 2025
Maintains: Buy
Price Target: $8 → $12
Current: $6.07
Upside: +97.69%
Clover Health Investments
Dec 17, 2024
Initiates: Buy
Price Target: $6
Current: $2.04
Upside: +194.12%
BioLife Solutions
Nov 13, 2024
Maintains: Buy
Price Target: $30 → $32
Current: $22.52
Upside: +42.10%
Omnicell
Oct 31, 2024
Maintains: Buy
Price Target: $45 → $64
Current: $41.25
Upside: +55.15%
Ligand Pharmaceuticals
Jul 9, 2024
Maintains: Buy
Price Target: $135 → $140
Current: $202.55
Upside: -30.88%
Inotiv
May 16, 2024
Maintains: Buy
Price Target: $25 → $10
Current: $0.31
Upside: +3,167.97%
Schrödinger
May 2, 2024
Maintains: Buy
Price Target: $35 → $30
Current: $12.15
Upside: +146.91%
MaxCyte
Nov 29, 2023
Initiates: Buy
Price Target: $7
Current: $0.79
Upside: +788.21%
Repligen
Aug 3, 2023
Maintains: Buy
Price Target: $207 → $200
Current: $124.97
Upside: +60.04%
Apr 13, 2023
Initiates: Buy
Price Target: $10
Current: $1.76
Upside: +468.18%
Apr 28, 2022
Maintains: Hold
Price Target: $67 → $30
Current: $5.16
Upside: +481.40%
Jan 4, 2022
Initiates: Buy
Price Target: $400
Current: $0.26
Upside: +153,687.01%